Nasdaq

Krystal Biotech, Inc. Welcomes Positive EMA Recommendation for VYJUVEK® Approval in Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for VYJUVEK® (beremagene geperpavec-svdt, or ...
Healio

FDA approves Vyjuvek for dystrophic epidermolysis bullosa

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vyjuvek (beremagene geperpavec-svdt) for patients aged six months or older. The topical, ...
The American Journal of Managed Care

Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Nasdaq

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization ...